These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 9409260

  • 1. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
    Huang Y, Rall SC, Mahley RW.
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y, Liu XQ, Rall SC, Mahley RW.
    J Biol Chem; 1998 Jul 10; 273(28):17483-90. PubMed ID: 9651338
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis.
    Huang Y, Schwendner SW, Rall SC, Sanan DA, Mahley RW.
    J Biol Chem; 1997 Sep 05; 272(36):22685-94. PubMed ID: 9312550
    [Abstract] [Full Text] [Related]

  • 6. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.
    Mahley RW, Huang Y, Rall SC.
    J Lipid Res; 1999 Nov 05; 40(11):1933-49. PubMed ID: 10552997
    [Abstract] [Full Text] [Related]

  • 7. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects.
    Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J, Davignon J.
    Arterioscler Thromb Vasc Biol; 1996 Jan 05; 16(1):149-59. PubMed ID: 8548416
    [Abstract] [Full Text] [Related]

  • 8. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW, van Vlijmen BJ, de Winther MP, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1999 Dec 05; 19(12):2945-51. PubMed ID: 10591674
    [Abstract] [Full Text] [Related]

  • 9. ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice.
    Hinsdale ME, Sullivan PM, Mezdour H, Maeda N.
    J Lipid Res; 2002 Sep 05; 43(9):1520-8. PubMed ID: 12235184
    [Abstract] [Full Text] [Related]

  • 10. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW, van Vlijmen BJ, van der Zee A, van't Hof B, van der Boom H, Kobayashi K, Chan L, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1998 Jan 05; 18(1):7-12. PubMed ID: 9445249
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W, Hoffmann MM, Scharnagl H, Fisher E, Chen M, Nauck M, Feussner G, Wieland H.
    J Lipid Res; 1998 Mar 05; 39(3):658-69. PubMed ID: 9548597
    [Abstract] [Full Text] [Related]

  • 13. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
    Ishigami M, Yamashita S, Sakai N, Hirano K, Hiraoka H, Nakamura T, Matsuzawa Y.
    Atherosclerosis; 2003 Jun 05; 168(2):359-66. PubMed ID: 12801620
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR, Rall SC, Brennan SO, Nye ER, George PM, Janus ED, Weisgraber KH.
    J Lipid Res; 1990 Mar 05; 31(3):535-43. PubMed ID: 2341812
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM, Scharnagl H, Panagiotou E, Banghard WT, Wieland H, März W.
    J Am Soc Nephrol; 2001 Mar 05; 12(3):524-530. PubMed ID: 11181800
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.